Literature DB >> 9360526

Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.

S K Grebe1, B McIver, I D Hay, P S Wu, L M Maciel, H A Drabkin, J R Goellner, C S Grant, R B Jenkins, N L Eberhardt.   

Abstract

Follicular thyroid carcinoma (FTC) exhibits frequent loss of heterozygosity (LOH) on chromosomes 10q and 3p, suggesting involvement of tumor suppressor genes. We screened 14 FTC (10 Hurthle cell carcinomas and 4 nonoxyphilic FTC), 14 papillary thyroid carcinomas, and 7 follicular adenomas for LOH on chromosome arms 1p, 3p, 3q, 10p, 10q, 11p, 11q, 13q, 17p, and 17q. LOH was more frequent in FTC than in follicular adenoma or papillary thyroid carcinoma. In FTC, rates of LOH on 3p (86%), 17p (72%), and 10q (57%) were higher than the average rate of LOH (33%; P < 0.05). Most frequently involved were 3p21-25 and 17p13.1-13.3, the sites for the VHL (3p25-26) and p53 (17p13.1) tumor suppressors. We, therefore, characterized these genes by dideoxy fingerprinting and DNA sequencing. Two FTC had mutations in p53, but only 1 of these exhibited LOH at 17p. No VHL gene mutations were found. Thus, neither p53 nor VHL genes play a significant role in the pathogenesis of differentiated thyroid cancer. LOH on 17p, but not on 3p or 10q, was correlated with mortality. Accordingly, 3p and 10q LOH may represent early, and 17p LOH late, events in FTC development. The data suggest the presence of novel tumor suppressor genes on chromosomes 3p and 17p that may be important in the pathogenesis of FTC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360526     DOI: 10.1210/jcem.82.11.4352

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.

Authors:  Janete M Cerutti; Rosana Delcelo; Marcelo João Amadei; Claudia Nakabashi; Rui M B Maciel; Bercedis Peterson; Jennifer Shoemaker; Gregory J Riggins
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.

Authors:  Axel Hoos; Alexander Stojadinovic; Bhuvanesh Singh; Maria E Dudas; Denis H Y Leung; Ashok R Shaha; Jatin P Shah; Murray F Brennan; Carlos Cordon-Cardo; Ronald Ghossein
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 4.  P53 mutations in thyroid carcinoma: tidings from an old foe.

Authors:  N R Farid
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

5.  DNA copy number changes in thyroid carcinoma.

Authors:  S Hemmer; V M Wasenius; S Knuutila; K Franssila; H Joensuu
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

6.  Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.

Authors:  Elena N Voropaeva; Tatyana I Pospelova; Mikhail I Voevoda; Vladimir N Maksimov; Yuriy L Orlov; Olga B Seregina
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

Review 7.  The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.

Authors:  Norman L Eberhardt; Stefan K G Grebe; Bryan McIver; Honey V Reddi
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

8.  Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression.

Authors:  Celina G. Kleer; Bonita R. Bryant; Thomas J. Giordano; Mark Sobel; Maria J. Merino
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

9.  Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.

Authors:  Raoul Hinze; Carsten Boltze; Axel Meye; Hans-Jürgen Holzhausen; Henning Dralle; Friedrich-Wilhelm Rath
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

10.  New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer.

Authors:  Andrzej J Lachinski; Tomasz Stefaniak; Jarek Kobiela; Saxon Connor; Zbigniew Gruca; Zbigniew Sledzinski
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.